Lymphoma News Today

Skip to content
  • Home
  • News Categories
    • Social Clips
    • Hodgkin’s Lymphoma
    • Non-Hodgkin’s Lymphoma
    • Clinical Trial
    • Leukemia & Lymphoma Society
  • About Lymphoma
    • Types Of Lymphoma
      • B-Cell Lymphoma
      • Benign Lymphoma
      • Burkitt’s Lymphoma
      • Cutaneous Lymphoma
      • Follicular Lymphoma
      • Indolent Lymphoma
      • Intestinal Lymphoma
      • Low Grade Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
    • Lymphoma Symptoms
      • Lymphedema
    • Signs Of Lymphoma
    • Lymphoma Diagnosis
    • Lymphoma Prognosis
  • Treatments
    • Approved Treatments
      • CAR T-cell Therapy
        • Kymriah (Tisagenlecleucel)
        • Yescarta (KTE-C19)
      • Adcetris (Brentuximab Vedotin)
      • Aliqopa (Copanlisib)
      • Arzerra (Ofatumumab)
      • Beleodaq (Belinostat)
      • Bendamustine in Lymphomas
      • Besponsa (Inotuzumab Ozogamicin)
      • Calquence (Acalabrutinib)
      • CPX-351
      • Gazyva (Obinutuzumab)
      • Imbruvica (Ibrutinib)
      • Keytruda for Classical Hodgkin Lymphoma (cHL)
      • Rituxan (Rituximab)
      • Rituxan Hycela
      • Revlimid (lenalidomide)
      • Velcade (bortezomib)
      • Venclexta (Venetoclax)
      • Zydelig (Idelalisib)
    • Experimental Treatments
      • ABP798 for Non-Hodgkin’s Lymphoma
      • ADCT-301 in Lymphomas
      • AFM11 for B-Cell Lymphoma
      • AFM13 for Hodgkin’s Lymphoma
      • ALT-803 for Non-Hodgkin Lymphomas
      • Betalutin
      • CMD-003 for Hodgkin’s and non-Hodgkin’s Lymphomas
      • CX-072
      • CPI-818
      • DI-Leu16-IL2
      • Duvelisib
      • GWN323
      • IGN002 for Non-Hodgkin’s Lymphoma
      • Imfinzi (Durvalumab)
      • JCAR017 for B-Cell Non-Hodgkin’s Lymphoma (NHL)
      • JCAR018
      • KTE-X19
      • Mogamulizumab
      • NM-IL-12
      • Oncoquest-L for Follicular Lymphoma
      • OXS-1550
      • PDR001 in Lymphoma
      • Resimmune
      • RG7741 (GDC-0575)
      • Tecentriq (Atezolizumab)
      • TG-1101 (Ublituximab)
      • TGR-1202 (Umbralisib)
      • Xalkori (Crizotinib)
  • Columns
    • Overcoming Adversity
    • Things That Give Me Hope
    • Life After Lymphoma: A Young Warrior’s Guide to Recovery
  • Information About COVID-19

Non-Hodgkin Lymphoma Study of Novartis’ T-cell Therapy Shows Early Efficacy

December 9, 2015May 13, 2016
Ines Martins, PhDby Ines Martins, PhD

In News.

Non-Hodgkin Lymphoma Study of Novartis’ T-cell Therapy Shows Early Efficacy

Click here to subscribe to the Lymphoma News Today Newsletter!

0
(0)

Novartis has released findings from a Phase 2a study evaluating the safety and efficacy of its novel chimeric antigen receptor T-cell (CART) immunotherapy CTL019 in two types of relapsed or refractory non-Hodgkin Lymphoma. The data was presented in an oral session at the  American Society of Hematology’s (ASH) recent annual meeting.

Results of study, entitled “Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas,” revealed an overall treatment response rate (ORR) at three months of 47% in adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and 73% in adults with follicular lymphoma (FL).

“These data add to the growing body of clinical evidence on CTL019 and illustrate its potential benefit in the treatment of relapsed and refractory non-Hodgkin lymphoma, a disease with few effective options,” study leader Stephen Schuster, MD, associate professor at the Division of Hematology/Oncology at the University of Pennsylvania, Abramson Cancer Center, said in a press release. “We look forward to continuing this study to further understand longer-term patient response.”

The study comprised 26 patients, all adults, 15 with DLBCL and 11 with FL. Results showed that three of the DLBCL patients with a partial response (PR) to CTL019 treatment at three months converted to complete response (CR) at six months. A similar six-month CR was found in three patients with FL. One DLBCL patient with a three-month PR showed disease progression at month six, and one FL patient with a three-month PR showed progression at 12 months post-treatment. Median progression-free survival was 11.9 months for FL patients and three months for DLBCL patients.

Four study patients developed a grade 3 or higher cytokine release syndrome (CRS), a condition observed when the engineered cells in the CTL019 infusion activate and multiply inside a patient’s body. Patients with CRS usually experience flu-like symptoms, including high fevers, nausea, muscle pain, and, in some cases, a drop in blood pressure and difficulties in breathing. Neurologic toxicity was observed in two other patients, including one grade 3 episode of delirium and one possibly related grade 5 encephalopathy.

CTL019 is individually manufactured, with a patient’s T cells collected through a blood draw called leukapheresis and  reprogrammed to target cancer and other B cells displaying CD19. The patient’s own modified cells are then reintroduced into the body. The cells are treated at a Novartis facility in Morris Plains, New Jersey, the first FDA-approved Good Manufacturing Practices site for cell therapy production in the United States. The facility is now processing cells for ongoing Phase 2 multi-center global studies of CTL019 in specific types of leukemia and lymphoma.

“The company’s investment in our state-of-the-art manufacturing facility has given us the capacity and scalability needed to support our growing global clinical trial program,” said Usman Azam, MD, global head, Cell & Gene Therapies Unit at Novartis. “Novartis is proud to be the first healthcare company to initiate Phase II CART therapy trials in the US, Europe, Canada and Australia. This is a significant step forward in our mission to help address unmet medical needs of patients.”

  • Author Details
Ines Martins, PhD
Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
×
Ines Martins, PhD
Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
Latest Posts
  • ATG-019 Phase 1 trial
  • ME-401, FDA fast track
  • Tafasitamab combo, lymphoma
  • blood biomarkers
Print Friendly, PDF & EmailPrint This Page

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Tagged B-cell non-Hodgkin lymphoma, B-cell-like diffuse large B-cell lymphomas, cART, clinical trials, CTL019, follicular lymphoma, immunotherapy, Novartis.

Post navigation

Previous: Do You Know The American Cancer Society Fight Back Line Dance?
Next:Yvonne’s Story and Her Fight Against Hodgkin’s Lymphoma

Recent Posts

  • farewell, honesty, impact, sometimes, superheroes

    A Farewell Note to My Beloved Readers

    February 26, 2021

  • farewell, honesty, impact, sometimes, superheroes

    A Light-giver Shares a Lesson in Emotional Honesty

    February 15, 2021

  • farewell, honesty, impact, sometimes, superheroes

    Embarking on a New Chapter While Cherishing the Value of Community

    February 1, 2021

Featured Posts

FDA Grants Orphan Drug Status to Umbralisib for Follicular Lymphoma

March 19, 2020

Umbralisib orphan drug

The Paradox of Healing

March 9, 2020

grateful, happiness, coronavirus, beauty
Visit Lymphoma News Today's profile on Pinterest.

Lymphoma News Today

BioNews Services, LLC
3 W Garden St
Suite 700
Pensacola, FL 32502
Email: [email protected]
Phone: +1-800-936-1363
  • About Us
  • Our Team
  • Our Guiding Ethics
  • Contact Us
  • Terms of Service
  • Privacy Policy
  • Disable Notifications

Disclaimer:

Lymphoma News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Copyright © 2013-2022 Copyright 2015 © All rights reserved